UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for mesothelioma in the United Kingdom. Explore treatment pathways including immunotherapy, chemotherapy, and novel targeted approaches.
The UK has the highest mesothelioma rate in the world due to historical asbestos use, with ~2,700 new cases per year. This cancer affects the lining of the lungs (pleural, most common) or abdomen (peritoneal). It typically develops 20-50 years after asbestos exposure. Prognosis has historically been poor, but immunotherapy has brought significant improvements. Shipyard workers, construction workers, and teachers are among those most at risk.
First-line treatment: nivolumab + ipilimumab (dual immunotherapy) is now the standard of care, approved by NICE in 2021. This was a major advance over chemotherapy alone. Alternative: pemetrexed + cisplatin chemotherapy. Second-line: re-challenge with immunotherapy or clinical trials. Peritoneal mesothelioma may benefit from cytoreductive surgery + HIPEC (heated intraperitoneal chemotherapy).
Immunotherapy has transformed mesothelioma treatment. The CheckMate-743 trial showed nivolumab + ipilimumab significantly improved survival vs chemotherapy, particularly for non-epithelioid subtypes. New approaches in trials include: checkpoint inhibitor combinations, mesothelin-targeted therapies (CAR-T cells, antibody-drug conjugates), cancer vaccines, and gene therapy approaches.
The UK is a global leader in mesothelioma research through the National Mesothelioma Research Programme and Mesothelioma UK charity. Active trials include: novel immunotherapy combinations, mesothelin-targeted CAR-T cells, photodynamic therapy, gene therapy, and supportive care interventions. Many trials are available through NHS thoracic oncology centres.
8 recruiting trials — 1 early-stage, 3 recurrent or metastatic, 4 stage not specified
Free AI-powered matching - no signup required
Search pleural mesothelioma Trials →